Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Trastuzumab plus FOLFOX for HER2-positive biliary tract cancer refractory to gemcitabine and cisplatin: a multi-institutional phase 2 trial of the Korean Cancer Study Group (KCSG-HB19–14)
Choong‐kun Lee, Hong Jae Chon, Jaekyung Cheon, et al.
˜The œLancet. Gastroenterology & hepatology (2022) Vol. 8, Iss. 1, pp. 56-65
Closed Access | Times Cited: 84

Showing 1-25 of 84 citing articles:

Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
James J. Harding, Jia Fan, Do‐Youn Oh, et al.
The Lancet Oncology (2023) Vol. 24, Iss. 7, pp. 772-782
Open Access | Times Cited: 116
Cholangiocarcinoma — novel biological insights and therapeutic strategies
Sumera I. Ilyas, Silvia Affò, Lipika Goyal, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 7, pp. 470-486
Open Access | Times Cited: 87
Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M.F. Mosele, C. Benedikt Westphalen, A Stenzinger, et al.
Annals of Oncology (2024) Vol. 35, Iss. 7, pp. 588-606
Open Access | Times Cited: 80
Artificial Intelligence in Breast Cancer Diagnosis and Personalized Medicine
Jong Seok Ahn, Sangwon Shin, Su‐A Yang, et al.
Journal of Breast Cancer (2023) Vol. 26, Iss. 5, pp. 405-405
Open Access | Times Cited: 49
Tucatinib and Trastuzumab for Previously Treated Human Epidermal Growth Factor Receptor 2–Positive Metastatic Biliary Tract Cancer (SGNTUC-019): A Phase II Basket Study
Yoshiaki Nakamura, Nobumasa Mizuno, Yu Sunakawa, et al.
Journal of Clinical Oncology (2023) Vol. 41, Iss. 36, pp. 5569-5578
Open Access | Times Cited: 47
New clinical trial design in precision medicine: discovery, development and direction
Xiao-Peng Duan, Bao‐Dong Qin, Xiao‐Dong Jiao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 46
Pre-activated nanoparticles with persistent luminescence for deep tumor photodynamic therapy in gallbladder cancer
Sarun Juengpanich, Shijie Li, Taorui Yang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 43
Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives
B. Ten Haaft, Manuel Pedregal, J Prato, et al.
European Journal of Cancer (2024) Vol. 199, pp. 113564-113564
Open Access | Times Cited: 19
HER2-targeted therapies beyond breast cancer — an update
Jeesun Yoon, Do‐Youn Oh
Nature Reviews Clinical Oncology (2024) Vol. 21, Iss. 9, pp. 675-700
Closed Access | Times Cited: 15
New Challenges in the Management of Cholangiocarcinoma: The Role of Liver Transplantation, Locoregional Therapies, and Systemic Therapy
Ezequiel Mauro, Joana Ferrer, Tamara Saurí, et al.
Cancers (2023) Vol. 15, Iss. 4, pp. 1244-1244
Open Access | Times Cited: 25
Trastuzumab Deruxtecan in Human Epidermal Growth Factor Receptor 2–Expressing Biliary Tract Cancer (HERB; NCCH1805): A Multicenter, Single-Arm, Phase II Trial
Akihiro Ohba, Chigusa Morizane, Yasuyuki Kawamoto, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 27, pp. 3207-3217
Closed Access | Times Cited: 10
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
Gaël S. Roth, Loïc Verlingue, Matthieu Sarabi, et al.
European Journal of Cancer (2024) Vol. 202, pp. 114000-114000
Open Access | Times Cited: 8
New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe
Lorenza Rimassa, Ángela Lamarca, Grainne M. O’Kane, et al.
The Lancet Regional Health - Europe (2025) Vol. 50, pp. 101170-101170
Open Access | Times Cited: 1
Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB)
Vikas Ostwal, Sarika Mandavkar, Prabhat Bhargava, et al.
Journal of Clinical Oncology (2023) Vol. 42, Iss. 7, pp. 800-807
Closed Access | Times Cited: 16
Unresectable biliary tract cancer: Current and future systemic therapy
Danmei Zhang, Klara Dorman, C. Benedikt Westphalen, et al.
European Journal of Cancer (2024) Vol. 203, pp. 114046-114046
Open Access | Times Cited: 7
Concordance of ctDNA and tissue genomic profiling in advanced biliary tract cancer
Sohyun Hwang, Seonjeong Woo, Beodeul Kang, et al.
Journal of Hepatology (2024)
Closed Access | Times Cited: 5
Biliary Tract Cancers: Treatment Updates and Future Directions in the Era of Precision Medicine and Immuno-Oncology
Ashish Manne, Edward Woods, Allan Tsung, et al.
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 33
Changing Landscape of Systemic Therapy in Biliary Tract Cancer
Edward Woods, Dat Tan Le, Bharath Kumar Jakka, et al.
Cancers (2022) Vol. 14, Iss. 9, pp. 2137-2137
Open Access | Times Cited: 24
Practical guidelines for molecular testing of cholangiocarcinoma in clinical practice: Italian experts’ position paper
Matteo Fassan, Valentina Angerilli, Nicola Normanno, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 194, pp. 104224-104224
Open Access | Times Cited: 5
New systemic treatment options for advanced cholangiocarcinoma
Valentina Zanuso, Giulia Tesini, Elena Valenzi, et al.
Journal of Liver Cancer (2024) Vol. 24, Iss. 2, pp. 155-170
Open Access | Times Cited: 4
Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes as a predictive biomarker for immune checkpoint inhibitors in biliary tract cancer
Yeong Hak Bang, Choong‐kun Lee, Kyunghye Bang, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 20, pp. 4635-4643
Closed Access | Times Cited: 4
Recent 5‑year trends in biliary tract cancer survival rates: An analytical big data survey
Ji Yoon Lee, Ju Won Kim
Medicine International (2025) Vol. 5, Iss. 2
Closed Access
Own experience of using anti-HER2 therapy for cancer of the intrahepatic cholangiocarcinoma
P. V. Golubev, Evgenia Kuzmina, И. А. Покатаев, et al.
Medical alphabet (2025), Iss. 32, pp. 14-18
Closed Access
Update for: New developments in systemic therapy for advanced biliary tract cancer
Chigusa Morizane, Makoto Ueno, Masafumi Ikeda, et al.
Japanese Journal of Clinical Oncology (2025)
Closed Access
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma
Younghoon Kim, Jaewon Song, Namkyoung Kim, et al.
RSC Medicinal Chemistry (2025)
Closed Access
Page 1 - Next Page

Scroll to top